Terasil-D (Therasil-D)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceDextromethorphan + Phenylephrine + ChlorproenamineDextromethorphan + Phenylephrine + Chlorproenamine
Similar drugsTo uncover
  • Terasil-D
    syrup inwards 
    Plethiko Pharmaceuticals Co., Ltd.     India
    • Dosage form: & nbspsyrup
    Composition:

    5 ml of syrup contain:

    active substances: dextromethorphan hydrobromide monohydrate 10.0 mg, phenylephrine hydrochloride 5.0 mg, chlorphenamine maleate 2.0 mg;

    Excipients: sucrose, sodium methylparahydroxybenzoate, sodium propylparahydroxybenzoate, bronopol, sodium saccharinate dihydrate, propylene glycol, levomenthol, citric acid monohydrate, quinoline yellow dye, fruit flavor, water.

    Description:

    A liquid of yellow color with a weak fruit taste.

    Pharmacotherapeutic group:antitussive combination
    ATX: & nbsp

    R.05.X   Other combined drugs used for catarrhal diseases

    Pharmacodynamics:

    Combined drug, the effect of which is due to its constituent components: antitussive, vasoconstrictive and anti-allergic effect.

    Dextromethorphan is an antitussive drug, it is close to codeine by force of action, raises the threshold of sensitivity of the cough center of the medulla oblongata, suppresses dry cough (of various etiologies). Has some sedative effect.Does not have analgesic, narcotic and hypnotic effects, does not depress the respiratory center. The onset of action is 10-30 minutes after administration; duration - for 5-6 hours in adults and up to 6-9 hours in children.

    Phenylephrine - alpha-adrenomimetic, has vasoconstrictive effect, helps to eliminate nasal congestion, facilitates nasal breathing.

    Chlorphenamine - H1-receptor blocker, has anti-allergic effect.

    Pharmacokinetics:

    No pharmacokinetics studies have been performed.

    Indications:

    Symptomatic therapy of dry irritating cough with "colds", acute respiratory infections and other acute and chronic diseases of the respiratory system.

    Contraindications:

    - Increased individual sensitivity to the components of the drug;

    - epilepsy;

    - hyperthyroidism;

    - bronchial asthma;

    - patients taking monoamine oxidase inhibitors (MAO);

    - children's age (up to 6 years);

    - pregnancy and lactation.

    Carefully:

    - Cardiac ischemia;

    - recently suffered myocardial infarction;

    - angle-closure glaucoma;

    - retention of urine;

    - hyperplasia of the prostate.

    Dosing and Administration:

    Inside, squeezed a little water.

    Recommended dose for adults - 5-7,5 ml of syrup 3-4 times a day. Recommended dose for children over 6 years - 2.5-3.5 ml of syrup 3-4 times a day.

    Side effects:

    From the central nervous system: dizziness, headache, drowsiness, apathy, increased excitability, anxiety, euphoria, tinnitus, impaired coordination of movements, tremor, epileptiform convulsions.

    From the sense organs: blurred vision, mydriasis, paresis of accommodation, increased intraocular pressure.

    From the cardiovascular system: decrease or increase in blood pressure, tachycardia.

    From the digestive system: increased salivation, nausea, vomiting, diarrhea, constipation, dry mouth, anorexia, increased appetite, epigastric pain.

    From the hematopoiesis: anemia, thrombocytopenia, hemolytic anemia, aplastic anemia.

    From the urinary system: difficulty urinating, urinary retention, nephrotoxicity (papillary necrosis).

    Allergic reactions: skin rash, itching, angioedema, bronchial obstruction.

    Overdose:

    Symptoms: overdose phenylephrine can cause agitation, increased blood pressure and heart rhythm disturbances. Overdose dextromethorphan can cause excitation, dizziness, respiratory depression, impaired consciousness, lowering blood pressure, tachycardia, muscle hypertension, ataxia, dyspeptic disorders. Overdose caused by chlorphenamine: excitation, dizziness, sleep disturbances, dry mouth, urinary retention.

    Treatment: gastric lavage, symptomatic treatment, artificial ventilation. A specific antidote for dextromethorphan is nalaxone.

    Interaction:

    Dextromethorphan

    Strengthens the effect of narcotic antitussives and other drugs that depress the central nervous system (barbiturates, tranquilizers, neuroleptics, antidepressants).

    MAO inhibitors, furazolidone, procarbazine, selegiline with simultaneous application can cause adrenergic crisis, collapse, coma, dizziness, agitation, increased blood pressure, hyperpyrexia, intracranial hemorrhage, lethargy, nausea, spasms, tremor.

    Amiodarone, fluoxetine, quinidine, by inhibiting the cytochrome P450 system, can increase the concentration of the drug in the blood.

    Tobacco smoke can lead to increased secretion of glands on the background of inhibition of cough reflex.

    Phenylephrine

    Reduces the hypotensive effect of diuretics and hypotensive drugs (including methyldopy, mekamilamin, guanadrel, guanetidine). Guanethidine, in turn, enhances the alpha-adrenostimulating activity of phenylephrine.

    MAO inhibitors (incl. furazolidone, procarbazine, selegin), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the pressor effect and arrhythmogenicity of phenylephrine.

    Against the background of simultaneous reception of reserpine, an increase in blood pressure is possible (due to the depletion of catecholamine stores in adrenergic endings, sensitivity to adrenomimetics increases).

    Inhalation anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmia, as sharply increase the sensitivity of the myocardium to sympathomimetics.

    Ergometrine, ergotamine, methylergomethrin, oxytocin, doxapram increase the severity of the vasoconstrictor effect.

    Reduces the antianginal effect of nitrates.

    Chlorphenamine

    MAO inhibitors, furazolidone increase the risk of hypertensive crisis, agitation, hyperpyrexia.

    Special instructions:

    During treatment, it is necessary to refrain from using ethanol due to the fact that dextromethorphan enhances its effect.

    Chlorphenamine can suppress positive skin allergic tests, so the drug should be discarded a few days before the skin tests.

    Effect on the ability to drive transp. cf. and fur:During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:Syrup
    Packaging:For 60 ml and 100 ml in glass bottles of dark yellow color with an aluminum screw cap and a plastic measuring cup.
    Each vial with instructions for use in a cardboard box.
    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-003638/10
    Date of registration:30.04.2010
    The owner of the registration certificate:Plethiko Pharmaceuticals Co., Ltd. Plethiko Pharmaceuticals Co., Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspREZLOV ZAO REZLOV ZAO Kazakhstan
    Information update date: & nbsp15.01.2016
    Illustrated instructions
      Instructions
      Up